CURE bleeding criteria: Difference between revisions
Jump to navigation
Jump to search
m CURE moved to CURE bleeding criteria |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
Line 26: | Line 26: | ||
<br> | <br> | ||
[[Category:Medical emergencies]] | [[Category:Medical emergencies]] |
Revision as of 23:18, 8 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
CURE Clinical Trials:
[[The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial
Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events[1]
“ |
Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial hypotension requiring the use of intravenous inotropic agents) Hemoglobin decrease ≥5 g/dL or required ≥4 U of blood Other major bleeding Transfusion of 2–3 U, intraocular
Led to discontinuation of study drug |
” |
References
- ↑ Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006). "Adverse impact of bleeding on prognosis in patients with acute coronary syndromes". Circulation. 114 (8): 774–82. doi:10.1161/CIRCULATIONAHA.106.612812. PMID 16908769.
bg:Кръвоизлив bs:Krvarenje ca:Hemorràgia cs:Krvácení de:Blutung eu:Odoljario it:Emorragia he:דימום la:Haemorrhagia lt:Kraujavimas nl:Versterkte bloedingsneiging qu:Yawar apariy sv:Blödning